reports
Agilent to Announce Second-Quarter Fiscal Year 2024 Financial Results ...
SANTA CLARA, Calif.--(BUSINESS WIRE)-- Agilent Technologies Inc. (NYSE: A) will release financial results for the second quarter of fiscal year 2024 after the stock market closes on May 29. In addition, the company will host a conference call to discuss the results at 1:30 p.m. PT. To join the listen-only conference call webcast, click the link on the of Agilent’s investor relations website. A recording of the call will also be available on the website for 90 days. About Agilent Technologies Agilent Technologies Inc. (NYSE: A) is a global leader in analytical and clinical laboratory tec...
- Alison Turner
Pan American Silver - La Arena divestment
Pan American Silver (PAAS) has announced a sale of the La Arena and La Arena II projects to Zijin Mining for US$245m in cash, US$50m in a contingent payment and a 1.5% NSR gold royalty. La Arena II is a copper and gold sulphide deposit that sits underneath the currently producing La Arena gold project. We view the transaction as positive for PAAS, given La Arena’s very short mine life, significant capex required to bring La Arena II into production and the fact that copper is not PAAS’s core com...
Regeneron Reports First Quarter 2024 Financial and Operating Results
Regeneron Reports First Quarter 2024 Financial and Operating Results First quarter 2024 revenues decreased 1% to $3.15 billion versus first quarter 2023; excluding RonapreveTM(a)(b), revenues increased 7%First quarter 2024 Dupixent® global net sales (recorded by Sanofi) increased 24% to $3.08 billion versus first quarter 2023First quarter 2024 U.S. net sales for EYLEA® HD and EYLEA® were $1.40 billion, including $200 million from EYLEA HDFirst quarter 2024 Libtayo® global net sales increased 45% to $264 million versus first quarter 2023First quarter 2024 GAAP diluted EPS of $6.27 and non-GA...
Padraig McDonnell Assumes Agilent CEO Role
SANTA CLARA, Calif.--(BUSINESS WIRE)-- Agilent Technologies Inc. (NYSE:A) today announced that Padraig McDonnell has assumed the role of Agilent CEO, effective immediately. His appointment is part of the company’s CEO . McDonnell is the fourth CEO in Agilent’s history and succeeds Mike McMullen, who will serve as an adviser until he retires Oct. 31. This press release features multimedia. View the full release here: Padraig McDonnell (Photo: Business Wire) “It’s an incredible honor to serve as CEO of this great company that impacts the world by advancing the quality of life,” McDonnell said. ...
Agilent Announces the NovoCyte Opteon, a Cutting-Edge Spectral Flow Cy...
SANTA CLARA, Calif.--(BUSINESS WIRE)-- (NYSE: A) has announced the NovoCyte Opteon Spectral Flow Cytometer, propelling flow cytometry into a new era of and accessibility. This cutting-edge system sets a gold standard for acquiring, analyzing, and reporting flow data across diverse domains—from basic research to drug discovery and therapy development. The NovoCyte Opteon represents a significant leap forward in flow cytometry technology, with configurations ranging from three to five lasers and support for up to 73 high-quality detectors. It meets researchers’ needs for sophisticated, large-...
- Laura Chico
- Wedbush Research
LOGN LOGITECH INTERNATIONAL S.A.
VMW VMWARE INC. CLASS A
QRVO QORVO INC.
XNCR XENCOR INC.
XENE XENON PHARMACEUTICALS INC
WDC WESTERN DIGITAL CORPORATION
VYGR VOYAGER THERAPEUTICS INC.
TSLA TESLA INC
SIMON SILICON MOTION TECHNOLOGY CORPORATION SPONSORED ADR
SGMO SANGAMO THERAPEUTICS INC.
SBUX STARBUCKS CORPORATION
RWT REDWOOD TRUST INC.
RARE ULTRAGENYX PHARMACEUTICAL INC.
QCOM QUALCOMM INC
PSTG PURE STORAGE INC. CLASS A
PCRX PACIRA BIOSCIENCES INC.
NVDA NVIDIA CORPORATION
NVCR NOVOCURE LTD.
NTAP NETAPP INC.
NBIX NEUROCRINE BIOSCIENCES INC.
MU MICRON TECHNOLOGY INC.
MCD MCDONALD'S CORPORATION
KURA KURA ONCOLOGY INC.
KPTI KARYOPHARM THERAPEUTICS
INTC INTEL CORPORATION
GOOGL ALPHABET INC. CLASS A
GERN GERON CORP.
FTNT FORTINET INC.
FATE FATE THERAPEUTICS INC
EXLS EXLSERVICE HOLDINGS INC.
EAT BRINKER INTERNATIONAL INC.
DENN DENNY'S CORPORATION
CTMX CYTOMX THERAPEUTICS INC.
CMRX CHIMERIX INC
BPMC BLUEPRINT MEDICINES CORP.
BMRN BIOMARIN PHARMACEUTICAL INC.
BIIB BIOGEN INC.
AXTI AXT INC.
ARDX ARDELYX INC
SWKS SKYWORKS SOLUTIONS INC.
FRX_CN FENNEC PHARMACEUTICALS
2330 TAIWAN SEMICONDUCTOR MANUFACTURING CO. LTD.
2303 UNITED MICROELECTRONICS CORP.
TMHC TAYLOR MORRISON HOME CORPORATION
HPE HEWLETT PACKARD ENTERPRISE CO.
TWTR TWITTER INC.
UTHR UNITED THERAPEUTICS CORPORATION
CLSD CLEARSIDE BIOMEDICAL INC
ALBO ALBIREO PHARMA
ANAB ANAPTYSBIO INC.
KALA KALA PHARMACEUTICALS INC.
ARGX ARGENX ADS
MRSN MERSANA THERAPEUTICS
GTHX G1 THERAPEUTICS
ALPN ALPINE IMMUNE SCIENCES
AMZN AMAZON.COM INC.
AMD ADVANCED MICRO DEVICES INC.
AAPL APPLE INC.
MSFT MICROSOFT CORPORATION
IBM INTERNATIONAL BUSINESS MACHINES CORPORATION
APLS APELLIS PHARMACEUTICALS
DNLI DENALI THERAPEUTICS INC
RCUS ARCUS BIOSCIENCES
AVGO BROADCOM INC.
HEAR TURTLE BEACH CORP.
SURF SURFACE ONCOLOGY
SRRK SCHOLAR ROCK HOLDING CORPORATION
KNSA KINIKSA PHARMACEUTICALS
LQDA LIQUIDIA CORPORATION
REPL REPLIMUNE GROUP
AX AXOS FINANCIAL INC.
ARVN ARVINAS HOLDING
YMAB Y-MABS THERAPEUTICS
STRO SUTRO BIOPHARMA
PINS PINTEREST INC. CLASS A
BCEL ATRECA
DELL DELL TECHNOLOGIES INC CLASS C
STOK STOKE THERAPEUTICS
IGMS IGM BIOSCIENCES
SWTX SPRINGWORKS THERAPEUTICS
LC LENDINGCLUB CORP
SMCI SUPER MICRO COMPUTER
AQST INC.
IDYA AQUESTIVE THERAPEUTICS
PASG IDEAYA BIOSCIENCES
BDTX PASSAGE BIO
ACET BLACK DIAMOND THERAPEUTICS
CRSR ADICET BIO INC
ITOS CORSAIR GAMING
ZNTL ITEOS THERAPEUTICS
PRAX ZENTALIS PHARMACEUTICALS
FUBO PRAXIS PRECISION MEDICINES
TVTX FUBOTV
LSEA TRAVERE THERAPEUTICS INC
VRDN LANDSEA HOMES CORP (A)
DAWN VIRIDIAN THERAPEUTICS INC
ELEV DAY ONE BIOPHARMACEUTICALS INC
OMGA ELEVATION ONCOLOGY
LBPH OMEGA THERAPEUTICS
THRX LONGBOARD PHARMACEUTICALS
MRVL THESEUS PHARMACEUTICALS
STX INC.
DSGN MARVELL TECHNOLOGY INC
ATXS SEAGATE TECHNOLOGY HLDGS PLC
AVTE DESIGN THERAPEUTICS INC
GFS ASTRIA THERAPEUTICS INC
RLYB AEROVATE THERAPEUTICS INC
KRTX GLOBALFOUNDRIES INC
FUSN RALLYBIO CORP
VIGL KARUNA THERAPEUTICS INC
EWTX FUSION PHARMACEUTICALS INC
VIGIL NEUROSCIENCE INC
EDGEWISE THERAPEUTICS INC
- David Carlson
- David Nierengarten
- Dennis Pak
- Laura Chico
- Liana Moussatos
- Martin Fan
- Ritika Das
- Robert Driscoll
- Sam Ravina
XENE XENON PHARMACEUTICALS INC
VYGR VOYAGER THERAPEUTICS INC.
SGMO SANGAMO THERAPEUTICS INC.
RARE ULTRAGENYX PHARMACEUTICAL INC.
PCRX PACIRA BIOSCIENCES INC.
NVCR NOVOCURE LTD.
NBIX NEUROCRINE BIOSCIENCES INC.
KURA KURA ONCOLOGY INC.
KPTI KARYOPHARM THERAPEUTICS
GERN GERON CORP.
FATE FATE THERAPEUTICS INC
CTMX CYTOMX THERAPEUTICS INC.
CMRX CHIMERIX INC
BPMC BLUEPRINT MEDICINES CORP.
BMRN BIOMARIN PHARMACEUTICAL INC.
BIIB BIOGEN INC.
ARDX ARDELYX INC
FRX_CN FENNEC PHARMACEUTICALS
UTHR UNITED THERAPEUTICS CORPORATION
CLSD CLEARSIDE BIOMEDICAL INC
ALBO ALBIREO PHARMA
ANAB ANAPTYSBIO INC.
KALA KALA PHARMACEUTICALS INC.
ARGX ARGENX ADS
MRSN MERSANA THERAPEUTICS
GTHX G1 THERAPEUTICS
ALPN ALPINE IMMUNE SCIENCES
APLS APELLIS PHARMACEUTICALS
DNLI DENALI THERAPEUTICS INC
RCUS ARCUS BIOSCIENCES
SURF SURFACE ONCOLOGY
SRRK SCHOLAR ROCK HOLDING CORPORATION
KNSA KINIKSA PHARMACEUTICALS
LQDA LIQUIDIA CORPORATION
REPL REPLIMUNE GROUP
ARVN ARVINAS HOLDING
YMAB Y-MABS THERAPEUTICS
STRO SUTRO BIOPHARMA
BCEL ATRECA
STOK STOKE THERAPEUTICS
IGMS IGM BIOSCIENCES
SWTX SPRINGWORKS THERAPEUTICS
AQST AQUESTIVE THERAPEUTICS
IDYA IDEAYA BIOSCIENCES
PASG PASSAGE BIO
BDTX BLACK DIAMOND THERAPEUTICS
ACET ADICET BIO INC
ITOS ITEOS THERAPEUTICS
ZNTL ZENTALIS PHARMACEUTICALS
PRAX PRAXIS PRECISION MEDICINES
TVTX TRAVERE THERAPEUTICS INC
VRDN VIRIDIAN THERAPEUTICS INC
DAWN DAY ONE BIOPHARMACEUTICALS INC
ELEV ELEVATION ONCOLOGY
OMGA OMEGA THERAPEUTICS
LBPH LONGBOARD PHARMACEUTICALS
THRX THESEUS PHARMACEUTICALS
DSGN INC.
ATXS DESIGN THERAPEUTICS INC
AVTE ASTRIA THERAPEUTICS INC
RLYB AEROVATE THERAPEUTICS INC
KRTX RALLYBIO CORP
FUSN KARUNA THERAPEUTICS INC
VIGL FUSION PHARMACEUTICALS INC
EWTX VIGIL NEUROSCIENCE INC
EDGEWISE THERAPEUTICS INC
Fortuna renews share repurchase program
Fortuna renews share repurchase program VANCOUVER, British Columbia, April 30, 2024 (GLOBE NEWSWIRE) -- Fortuna Silver Mines Inc. (TSX: FVI) (NYSE: FSM) announced today that the Toronto Stock Exchange has approved the renewal of Fortuna’s normal course issuer bid (the “NCIB”) to purchase up to five percent of its outstanding common shares. Under the NCIB, purchases of common shares may be made through the Toronto Stock Exchange, the New York Stock Exchange and/or alternative Canadian trading systems. The share repurchase program starts on May 2, 2024 and will expire on the earlier of: ...
Agilent Names Simon May to Lead Diagnostics and Genomics Group
SANTA CLARA, Calif.--(BUSINESS WIRE)-- Agilent Technologies, Inc. (NYSE: A) today announced Simon May has been named president of the company’s Diagnostics and Genomics Group (DGG). May, previously executive vice president and president of the Life Science Group at Bio-Rad Laboratories, will join Agilent on May 6. “We are excited to welcome Simon May to the Agilent team,” said Padraig McDonnell, COO and CEO-elect. “Simon’s deep technical knowledge, his broad range of experience, and his career-long focus on strategy, continuous improvement and operational excellence are critical additions to...
EYLEA® HD (aflibercept) Injection 8 mg Presentations at ARVO Reinforce...
EYLEA® HD (aflibercept) Injection 8 mg Presentations at ARVO Reinforce Sustained and Clinically Meaningful Outcomes in Serious Retinal Diseases Long-term data and subgroup analyses from pivotal EYLEA HD clinical program continue to demonstrate durable efficacy and consistent safety in patients with wet age-related macular degeneration and certain diabetic eye diseases TARRYTOWN, N.Y., April 29, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the presentation of positive long-term results and subgroup analyses from the pivotal clinical program of E...
- David Carlson
- David Nierengarten
- Dennis Pak
- Laura Chico
- Martin Fan
- Ritika Das
- Robert Driscoll
- Sam Ravina
RARE ULTRAGENYX PHARMACEUTICAL INC.
NVCR NOVOCURE LTD.
NBIX NEUROCRINE BIOSCIENCES INC.
KURA KURA ONCOLOGY INC.
GERN GERON CORP.
CMRX CHIMERIX INC
BPMC BLUEPRINT MEDICINES CORP.
ARDX ARDELYX INC
UTHR UNITED THERAPEUTICS CORPORATION
GTHX G1 THERAPEUTICS
SWTX SPRINGWORKS THERAPEUTICS
- Laura Chico
Regeneron and Mammoth Biosciences Collaborate to Pursue Next-Generatio...
Regeneron and Mammoth Biosciences Collaborate to Pursue Next-Generation CRISPR-Based Gene Editing for Multiple Diseases Mammoth’s proprietary ultracompact CRISPR-based gene editing platform and Regeneron’s proprietary delivery technologies set to advance in vivo programs in multiple tissue and cell types Mammoth to receive $100 million total upfront payment and equity investment from Regeneron at signing TARRYTOWN, N.Y., April 25, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) and Mammoth Biosciences, Inc., today announced a collaboration to research, develop and...
Regeneron to Showcase Progress in Advancing Novel Investigational Trea...
Regeneron to Showcase Progress in Advancing Novel Investigational Treatment Approaches for a Broad Range of Solid Tumors and Blood Cancers at ASCO Oral presentation will feature new data for investigational REGN7075, an EGFRxCD28 costimulatory bispecific with the potential to enhance the treatment of certain advanced solid tumors in combination with Libtayo® (cemiplimab-rwlc) 17 presentations to highlight Regeneron's investigational pipeline including checkpoint inhibitors, CD3 bispecifics and CD28 costimulatory bispecifics TARRYTOWN, N.Y., April 24, 2024 (GLOBE NEWSWIRE) -- Reg...
MAG Announces First Quarter 2024 Production From Juanicipio
MAG Announces First Quarter 2024 Production From Juanicipio VANCOUVER, British Columbia, April 24, 2024 (GLOBE NEWSWIRE) -- MAG Silver Corp. (TSX / NYSE American: MAG) (“MAG” or “MAG Silver”) reports production from Juanicipio (56% / 44% Fresnillo plc (“Fresnillo”) and MAG, respectively) for the first quarter (“Q1”) ended March 31, 2024. Q1 Highlights Solid throughput: Juanicipio processed 325,684 tonnes of ore in Q1. Despite a routine 4 day maintenance shutdown during the quarter, Juanicipio delivered 3,980 tonnes per operating day milling performance confirming its operational efficie...
- Laura Chico
Regeneron to Highlight Advances in Genetic Medicine Research at Americ...
Regeneron to Highlight Advances in Genetic Medicine Research at American Society of Gene and Cell Therapy (ASGCT) Oral presentations include updated results from clinical study of otoferlin gene therapy DB-OTO demonstrating restoration in children with profound genetic hearing loss Additional presentations cover progress in novel genetic medicine delivery systems and immune response modulation TARRYTOWN, N.Y., April 22, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that new and updated data across its genetic medicines portfolio will be pres...
Fortuna to release first quarter 2024 financial results on May 7, 2024...
Fortuna to release first quarter 2024 financial results on May 7, 2024; Conference call at 12 p.m. Eastern Time on May 8, 2024 VANCOUVER, British Columbia, April 22, 2024 (GLOBE NEWSWIRE) -- Fortuna Silver Mines Inc. (NYSE: FSM) (TSX: FVI) announces that it will release its unaudited financial statements and MD&A for the first quarter on Tuesday, May 7, 2024, after the market closes. A conference call to discuss the financial and operational results will be held on Wednesday, May 8, 2024, at 9:00 a.m. Pacific Time | 12:00 p.m. Eastern Time. Hosting the call will be Jorge A. Ganoza, Presi...
- Laura Chico
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.